- Eli Lilly's drug solanezumab failed to slow cognitive decline in patients treated before they showed symptoms.
- The drug was designed to target only soluble forms of amyloid beta, a toxic protein that accumulates in the brains of people with Alzheimer's.
- The U.S. drugmaker is in late-stage development with two other Alzheimer's drugs, donanemab and remternetug, that specifically target deposited amyloid and have been shown to clear plaque in treated patients.
- Lilly expects to announce results from a Phase III trial of donanemab for early Alzheimer's before the end of June.
- The company is conducting a 3,300-patient trial of donanemab in asymptomatic Alzheimer's patients.
Older Eli Lilly's drug fails Alzheimer's prevention trial
An early-generation Alzheimer's drug from Eli Lilly and Co failed to slow cognitive decline in patients treated before they showed symptoms, but the large trial found a strong link between levels of brain plaques and disease progression, the company said on Wednesday.
/cloudfront-us-east-2.images.arcpublishing.com/reuters/FXRJC64ERFLQXCC6J6I64M2ZVI.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/RCWZE2OK3BNCJNRVFOS74NYF7M.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/6W5WJY7T4NLKVFJO5JX37LPYS4.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/BYL7ESQPMFMSNNVJSVCYKYTPH4.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/OGBROYPEZVMVNLCKMBDIE2XJCE.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/JG3AL7UAGVPBJHJUNQS4YZL4SE.jpg)
/cloudfront-us-east-2.images.arcpublishing.com/reuters/FXRJC64ERFLQXCC6J6I64M2ZVI.jpg&description=Older%20Eli%20Lilly's%20drug%20fails%20Alzheimer's%20prevention%20trial){kind=link}